Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Project Grant

University of Toronto

$684,675.00

Auger Electron Radioimmunotherapy for Treatment and Prevention of Metastases from Triple-Negative Breast Cancer

FY 2017-18

Summary
In this project, a team of investigators will develop a new radiation treatment for triple negative breast cancer (TNBC). TNBC is a poor prognosis form of breast cancer that has a high risk for spread throughout the body (metastases) as well as death. The new treatment is based on antibodies that bind to breast cancer cells, and that carry a radioactive material which will irradiate and kill these cells. The radioactive antibodies will be studied for eliminating breast cancer cells that have escaped into the blood from a tumour implanted into mice and for treatment of small metastases that have formed. If successful, the treatment may eventually be used to improve the outcome of patients with TNBC.
Program
Project Grant
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
369905
Name
Reilly Raymond M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Cancer Progression & Therapeutics
Projecttitle
Auger Electron Radioimmunotherapy for Treatment and Prevention of Metastases from Triple-Negative Breast Cancer
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$684,675
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Auger Electrons; Breast Cancer; Circulating Tumour Cells; Epidermal Growth Factor Receptors; Metastases; Positron Emission Tomography (Pet); Radioimmunotherapy; Triple-Negative Breast Cancer; Tumour Xenograft Mouse Models
Abstract
In this project, a team of investigators will develop a new radiation treatment for triple negative breast cancer (TNBC). TNBC is a poor prognosis form of breast cancer that has a high risk for spread throughout the body (metastases) as well as death. The new treatment is based on antibodies that bind to breast cancer cells, and that carry a radioactive material which will irradiate and kill these cells. The radioactive antibodies will be studied for eliminating breast cancer cells that have escaped into the blood from a tumour implanted into mice and for treatment of small metastases that have formed. If successful, the treatment may eventually be used to improve the outcome of patients with TNBC.
Competitiondate
201709
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Reilly, Raymond M
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $684,675~ $0~